Can-Fite
is an Israel-based biopharmaceutical company that researches and develops small-molecule therapeutics for the treatment of inflammatory, liver, and metabolic diseases... Read moreCan-Fite
is an Israel-based biopharmaceutical company that researches and develops small-molecule therapeutics for the treatment of inflammatory, liver, and metabolic diseases... Read more
News
Mar 30, 2026
StreetInsider
Press Release: Can-Fite : Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Mar 26, 2026
GlobeNewswire
Press Release: Can-Fite : Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Mar 26, 2026
Seeking Alpha
Can-Fite: Can-Fite Biopharma GAAP EPS of -$5.97, revenue of $0.41M
Mar 17, 2026
GlobeNewswire
Press Release: Can-Fite : Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Mar 05, 2026
Zacks
Can-Fite: CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Mar 04, 2026
StreetInsider
Press Release: Can-Fite : Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 04, 2026
GlobalNewswire
Press Release: Can-Fite : Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Mar 04, 2026
RTTNews
Can-Fite: Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants
Mar 04, 2026
Benzinga
Can-Fite: Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study
Feb 17, 2026
GlobalNewswire
Press Release: Can-Fite : Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Can-Fite Competitors
1
2
3
4
5
6
7
8
9
10